| תיאור כללי: |
- Biomarker Development Award supports high-impact research aimed at qualifying or validating biomarkers for rapid transfer to clinical practice for prostate cancer. Projects studying multiple biomarkers are highly encouraged. Multi-institutional efforts are highly encouraged. Presentation of preliminary data demonstrating the suitability of the biomarker(s) for further testing toward clinical application is required. PIs must demonstrate availability and accessibility of samples and /or data, and are encouraged to leverage pre-existing resources, e.g., biospecimen banks. Funding: $2.25M over max 3 years.
- Clinical Exploration Award supports rapid execution of hypothesis-driven, early phase clinical trials or studies correlative to existing clinical trials to examine interventions that could have a major impact on prostate cancer clinical management. It is anticipated that proposed studies will explore innovative and untested concepts to provide scientific rationale or initial proof-of-principle for larger clinical trials in prostate cancer. Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other. Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place before submission of the application. Funding: $450K over 3 years.
- Laboratory - Clinical Transition Award supports product-driven preclinical studies of promising novel lead agents or medical devices that have the potential to revolutionize prostate cancer clinical care. For lead agents, PIs are expected to demonstrate within the application (1) a validated target, (2) access to either one lead agent or a limited number of lead agents for optimization, and (3) the agent’s mechanism of action. For lead agents, preliminary data should demonstrate validated target availability and distribution in relevant human tissues and substantive information from model systems that supports potential efficacy of the lead agent(s) in humans. For medical devices preliminary data should demonstrate reliability, reproducibility and effectiveness for the medical device. Supports research that ranges from preclinical study through cGMP production. Funding: max $1.5M over max 3 years.
- Transformative Impact Award supports prostate cancer research efforts with near-term, transformative impact for prostate cancer patients. Research efforts based on team science are expected, with support by a PI with a demonstrated record of successfully leading large, focused projects. Consistent with the goal of near-term benefit for patients, the scope of the research effort must include translational studies, clinical research, and/or clinical trials. Funding: max $6.0M over max 3 years.
- Synergistic Idea Development Award supports new or existing partnerships between two or three independent investigators to address a central innovative question or problem in prostate cancer that may include high risk, provided there is a potential for significant impact. Preliminary data are encouraged but not required. Synergy, Innovation, and Impact are the most important review criteria. Does not support clinical trials. Funding: max $750K over max 3 years.
https://cdmrp.org/Program_Announcements_and_Forms/
|
